BioNTech SE (NASDAQ:BNTX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of BioNTech SE (NASDAQ:BNTX) have been assigned a consensus recommendation of “Moderate Buy” from the seventeen brokerages that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $143.65.

A number of equities analysts recently weighed in on BNTX shares. HC Wainwright reissued a “buy” rating and set a $150.00 price objective on shares of BioNTech in a report on Monday, November 18th. Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and lifted their price target for the stock from $110.00 to $125.00 in a research note on Tuesday, November 19th. Morgan Stanley lowered their price objective on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a report on Tuesday. Wells Fargo & Company assumed coverage on shares of BioNTech in a report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 target price on the stock. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $171.44 price target on shares of BioNTech in a research note on Tuesday.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $98.39 on Friday. The company’s fifty day moving average price is $116.45 and its 200-day moving average price is $113.13. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The firm has a market capitalization of $23.59 billion, a price-to-earnings ratio of -46.85 and a beta of 0.30. BioNTech has a one year low of $76.53 and a one year high of $131.49.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.24 billion. During the same quarter in the prior year, the firm earned $1.90 earnings per share. The firm’s revenue was down 19.5% on a year-over-year basis. On average, equities research analysts anticipate that BioNTech will post -3.88 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. GSA Capital Partners LLP purchased a new position in shares of BioNTech during the third quarter valued at approximately $373,000. Baillie Gifford & Co. lifted its holdings in BioNTech by 0.4% during the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after purchasing an additional 31,773 shares in the last quarter. Victory Capital Management Inc. purchased a new position in shares of BioNTech in the third quarter valued at about $345,000. Planning Capital Management Corp raised its position in shares of BioNTech by 45,000.0% during the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after buying an additional 450 shares during the last quarter. Finally, OneDigital Investment Advisors LLC purchased a new position in shares of BioNTech during the third quarter valued at about $361,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.